Authors' recommendations: Cutaneous T-cell lymphoma is a rare form of non-Hodgkin lymphoma, a cancer affecting one type of white blood cell. At the beginning, lymphoma can be difficult to diagnose, but as the lymph nodes get bigger, a painless swelling in the neck, armpit or groin is sometimes noticed as well as raised, rash-like, itchy patches or lumps on the skin. By the time they are diagnosed, the lymphoma has often spread widely around the body. The main treatment is chemotherapy but as this disease mainly affects older people, not all patients are well enough to manage this, and the disease often returns after treatment. Mogamulizumab is a new drug for the treatment of cutaneous T-cell lymphoma that is injected into the bloodstream weekly or fortnightly. It is being studied at the moment to see how well it works and whether it is safe to use. If it is licensed for use in the UK, it would be a new treatment option that could improve the life expectancy of patients whose lymphoma has returned after their first treatment has stopped working.

Project Status: Completed

Year Published: 2016

URL for published report: http://www.hsric.nihr.ac.uk/topics/mogamulizumab-for-relapsed-or-refractory-cutaneous-t-cell-lymphoma-second-and-subsequent-lines/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)